Tags : Interpace Diagnostics

Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for

Shots: The companies will develop a pipeline of products used for diagnosing and assessing the risks of thyroid cancer, leveraging Interpace’s ThyGeNEXT and ThyraMIR assays combining with Helomics’ patient-derived tumor profiling and AI platform, D-CHIP Helomics to build a model utilizing Interpace’s clinical data which can be further used in identifying targets for treating indolent […]Read More